Usted está aquí
Mono-ovulation in women with polycystic ovary syndrome: a clinical review on ovulation induction
Reproductive BioMedicine Online, Volume 32, Issue 6, June 2016, Pages 563 - 583
Polycystic ovary syndrome (PCOS) affects 5–10% of women of reproductive age and is the most common cause of anovulatory infertility. The treatment approaches to ovulation induction vary in efficacy, treatment duration and patient friendliness. The aim was to determine the most efficient, evidence-based method to achieve mono-ovulation in women diagnosed with PCOS. Publications in English providing information on treatment, efficacy and complication rates were included until September 2015. Systematic reviews, meta-analyses and randomized controlled trials were favoured over cohort and retrospective studies. Clomiphene citrate is recommended as primary treatment for PCOS-related infertility. It induces ovulation in three out of four patients, the risk of multiple pregnancies is modest and the treatment is simple and inexpensive. Gonadotrophins are highly efficient in a low-dose step-up regimen. Ovulation rates are improved by lifestyle interventions in overweight women. Metformin may improve the menstrual cycle within 1–3 months, but does not improve the live birth rate. Letrozole is effective for ovulation induction, but is an off-label drug in many countries. Ovulation induction in women with PCOS should be individualized with regard to weight, treatment efficacy and patient preferences with the aim of achieving mono-ovulation and subsequently the birth of a singleton baby.
Keywords: assisted reproduction, BMI, clomiphene citrate, infertility, PCOS.
Polycystic ovary syndrome (PCOS) affects 5–10% of women of reproductive age and is the most common cause of anovulatory infertility (ESHRE Capri Workshop Group, 2012). The prevalence of PCOS depends on the diagnostic criteria used. According to the Rotterdam criteria, PCOS is characterized by at least two of the following three features: oligo- or anovulation (clinical); biochemical hyperandrogenism, or both; and polycystic ovarian morphology (PCOM) (ESHRE REA-SPCWG, 2004). In recent years, the Rotterdam criteria have been challenged by reports of a high prevalence of PCOM among young ovulatory women, partly due to the improvement in ultrasound technology (Duijkers and Klipping, 2010). It has been discussed whether the antral follicle threshold for the definition of PCOM should be changed or whether anti-Müllerian hormone could be used as an alternative marker of PCOM (Dewailly et al, 2011, Kristensen et al, 2010, and Lauritsen et al, 2015).
Polycystic ovary syndrome is a heterogeneous disorder, ranging from anovulatory women with polycystic ovaries without signs of hyperandrogenism to women with severe metabolic disturbance. The increased risk of type 2 diabetes and cardiovascular disease is associated with the increased prevalence of obesity in women with PCOS (Domecq et al, 2013 and ESHRE Capri Workshop Group, 2012). Moreover, ethnic variations in the presentation of symptoms of PCOS also play a role in the decision of treatment strategy (Alebic et al, 2015 and Wijeyaratne et al, 2011).
Several approaches to ovulation induction exist in women with PCOS. These approaches vary in efficacy, treatment duration and patient compliance. Moreover, new treatment strategies are continuously being introduced. A clinical update focusing on the current evidence-based practice is therefore highly warranted.
Materials and methods
Search methods, eligibility criteria and outcomes of interest were specified in advance. Outcomes of interest were chosen based on the following objectives of treatment efficacy: cycle regulation, ovulation, live birth rate, multiple births, patient friendliness and side-effects.
A systematic search of MEDLINE, EMBASE, and the Cochrane Library was conducted on all articles published up to September 2015. Additional records were identified by reference lists in retrieved articles.
Eligible articles were published in peer-reviewed journals and written in English. Articles not reporting on ovulation induction in the title or abstract were not included. Full-text articles were screened and the final inclusion decisions were made according to the following criteria: original studies, systematic reviews or meta-analyses; primary or first-line treatment and, if necessary, secondary treatment described; and treatment success, complications and side-effects described.
In the selected publications, data on treatment modalities were collected by two authors (KBP and NCF) (Table 1 and Table 2). The treatment modalities were divided into six main subjects: clomiphene citrate; exogenous gonadotrophins; metformin; lifestyle intervention; laparoscopic ovarian drilling (LOD); and letrozole.
|Reference||Study design, sample size (n)||Patients||Comparison||End point(s)||Results||P-value/95% CI||Comments||Conclusion of the present study||Level of evidence (1)||Country of origin|
|Rostami-Hodjegan et al. (2004)||Meta-analysis including 13 studies (n = 1762)||Not described in detail||Dose–response relationship of clomiphene||Ovulation rate||Ovulation rate of: 46% (50 mg*1), 70% (50 mg*2), 76% (50 mg*3) 85–90% after >150 mg* 5||P < 0.0001||Old studies, but based on a large cohort (n = 1760)||Case reports indicated that dosage based on plasma drug concentration monitoring could improve patient management, and an algorithm is proposed to facilitate treatment||1a||UK|
|Abu Hashim et al. (2015)||Meta-analysis including eight studies (n = 1373)||Women with PCOS and CC resistance||Metformin + CC vs. gonadotrophins: ovulation rate: three studies metformin + CC (n = 160) vs. gonadotrophins (n = 163); pregnancy rate: three studies metformin + CC (n = 160) vs. gonadotrophins (n = 163) ;||Ovulation rate; clinical pregnancy rate||Metformin + CC caused fewer ovulations (OR 0.25) and pregnancies (OR 0.45)||Ovulation rate:
P < 0.00001 95% CI (0.15 to 0.41); pregnancy rate: P < 0.002 95% CI (0.27 to 0.75)
|Most trials were conducted in North Africa (Egypt) and Asia. Subgroup analysis according to PCOS phenotype was not possible. The dose of metformin administered varied.||There is evidence for the superiority of gonadotrophins, but the metformin + CC combination is mainly relevant for clomiphene-resistant PCOS patients and, if not effective, a next step could be gonadotrophins. More attempts with metformin + CC are only relevant if there is limited access to gonadotrophins.||1a||Egypt|
|Metformin + CC vs. LOD: ovulation rate: two studies metformin + LOD (n = 163) vs. gonadotrophins (n = 169); pregnancy rate: two studies metformin + CC (n = 163) vs. LOD (n = 169)||No difference in ovulations (OR 0.88) or pregnancies (OR 0.96)||Ovulation rate: P = NS; 95% CI (0.53 to 1.47); pregnancy rate: P = NS; 95% CI (0.60 to 1.54)|
|Metformin + CC vs. aromatase inhibitors: ovulation rate: three studies metformin + CC vs. aromatase inhibitors (n = 409 total); pregnancy rate: two studies metformin + CC vs. aromatase inhibitors (n = 309 total)||No difference in ovulations (OR 0.88) or pregnancies (OR 0.96)||Ovulation rate: P = NS 95% CI (0.58 to 1.34); pregnancy rate: P = NS; 95% CI (0.53 to 1.36)|
|Nahuis et al. (2010)||Meta-analysis including six studies (n = 862)||Infertile women with PCOS (WHO group II) and CC resistance or CC failure||Recombinant gonadotrophins with urinary gonadotrophins||Ovulation rate; LBR rate; ongoing pregnancy rate; clinical pregnancy rate||Ovulation rate (OR 1.40); LBR (OR 1.12); ongoing pregnancy rate (OR 1.27); clinical pregnancy rate (OR 1.13)||Ovulation rate: 95% CI (1.03 to 1.92); LBR: 95% CI (0.75 to 1.66); ongoing pregnancy rate: 95% CI (0.78 to 2.07); clinical pregancy rate: 95% CI (0.67 to 1.89)||Ovulation rate was reported in all six studies; LBR in four; ongoing and clinical pregnancy rate in three studies.||No difference in effectiveness, safety and tolerability between recombinant and urinary follitropins.||1a||The Netherlands|
|Weiss et al. (2015)||Meta-analysis including 14 studies (n = 1726)||Infertile women with PCOS (WHO group II) and CC resistance||Recombinant FSH vs. urinary gonadotropins (10 RCTs) purified FSH vs. human menopausal gonadotrophin (four RCTs)||LBR pregnancy rate OHSS||Recombinant FSH vs. urinary gonadotrophins: LBR: OR 1.26; pregnancy rate: 1.08; OHSS 1.52||LBR: 95% CI (0.80 to 1.99); pregnancy rate: 95% CI (0.83 to 1.39); OHSS: 95% CI (0.81 to 2.84);||LBR: I2 = 65% OHSS: I2 = 65%;||No evidence of a difference in live birth and OHSS rates between urinary-derived gonadotrophins and recombinant FSH or human menopausal gonadotrophin and highly purified human menopausal gonadotrophin. Evidence for all outcomes was of low or very low quality||1a||The Netherlands|
|low rated quality of evidence.|
|Purified FSH vs. human menopausal gonadotrophin: LBR: OR 1.36; pregnancy rate: OR 1.44; OHSS: OR 9.95||LBR: 95% CI (0.58 to 3.18); pregnancy rate: 95% CI (0.55 to 3.77); OHSS: 95% CI (0.47 to 210)||LBR: I2 = 0%|
|Low to very low rated quality of evidence|
|Moazami Goudarzi et al. (2014)||Meta-analysis including six RCTs (n = 499)||Infertile women with PCOS (WHO group II) and CC resistance||LOD vs. gonadotrophins; Pregnancy rate: six RCTs; LBR: three RCTs; multiple pregnancies: three RCTs; spontaneous abortion: four RCTs||Pregnancy rate (primary outcome); LBR; multiple pregnancies; spontaneous abortion rate||Pregnancy rate: OR 0.53; pregnancy rate after LOD = 33% vs. pregnancy rate after gonadotrophin = 55%.||Pregnancy rate: 95% CI (0.24 to 1.18); P = NS||I2 = 73.2% (pregnancy rate); random effects model used; LBR: I2 = 3.35; multiple pregnancies: I2 = 0%. Spontaneous abortion: I2 = 0%.||No significant difference in clinical pregnancy rate and miscarriage rate between LOD and gonadotropin. Higher live birth rate after gonadotropin. Less multiple pregnancies following LOD. Suggest focus on long term effects of LOD on ovarian function.||1a||Iran|
|LBR: OR 0.44||LBR: 95% CI (0.26 to 0.74)|
|Multiple pregnancies: OR 0.12||Multiple pregnancies: 95% CI (0.03 to 0.57)|
|Spontaneous abortion: OR 0.59||Spontaneous abortion: 95% CI (0.27 to 1.29)|
|Franik et al. (2015)||Meta-analysis including 26 RCTs (n = 5560 women)||Anovulatory subfertile women with PCOS||Letrozole vs. placebo, CC and LOD LBR: Letrozole vs. placebo (one RCT, 36 CCR women); pregnancy rate: Letrozole vs. placebo (one RCT, 36 CCR women); LBR: letrozole vs. CC (nine RCTs, 1783 women); pregnancy rate: letrozole vs. CC and timed intercourse (15 RCTs, 2816 women); pregnancy rate: letrozole vs. CC and intrauterine insemination (three RCTs, 1597 women); LBR: letrozole vs. LOD (two RCTs, 407 women); pregnancy rate: letrozole (+metformin) vs. LOD (three RCTs, 553 women)||LBR; OHSS; Pregnancy rate||Letrozole vs. Placebo LBR: OR 3.17; clinical pregnancy: OR 3.17||LBR: 95% CI (0.12 to 83.17); clinical pregnancy: 95% CI (0.12 to 83.17)||Low rated quality of evidence. Adjuncts were added in some of the trials.||Letrozole seems to improve live birth and pregnancy rates compared with CC. Seems to be no difference between letrozole and LOD. OHSS was rare.||1a||Netherlands/ New Zealand|
|Letrozole vs. CC; LBR: OR 1.64 Letrozole vs. CC and timed intercourse: clinical pregnancy: OR 1.40; letrozole vs. CC and IUI: clinical pregnancy: OR 1.71||LBR: 95% CI (1.32 to 2.04); P = NS in favour of letrozole Clinical pregnancy (timed intercourse): 95% CI (1.18 to 1.65); clinical pregnancy (intrauterine insemination): 95% CI (1.30 to 2.25)|
|Letrozole vs. LOD; LBR: OR 1.19 Letrozole (+metformin) vs. LOD CP: OR 1.14||LBR: 95% CI (0.76 to 1.86); P = NS; clinical pregnancy: 95% CI (0.80 to 1.65)|
CC, clomiphene citrate; CCR, clomiphene citrate resistant; IUI, intrauterine insemination; LBR, live birth rate; LOD, laparoscopic ovarian drilling; NS, not statistically significant; OHSS, ovarian hyperstiulation syndrome; PCOS, polycystic ovary syndrome.
|Reference||Study design, sample size (n)||Patients||Comparison||End point(s)||Results||P- value/95% CI||Comments||Conclusion of the present study||Level of evidence (1)||Country of origin||Published in Journal|
|Lopez et al. (2004)||RCT (n = 76)||Infertile women with anovulatory PCOS, age <40 years; first treatment cycle||CC (50–150 mg/day for 5 days) (n = 38)||Women who ovulated at least once||RR 1.17 30/38 (79%) vs. 35/38 (92%)||P = NS; 95% CI 0.97 to 1.46||The trial was discontinued after 76 patients and 21 months because it was not possible to include the planned 152 women per treatment group in a reasonable time period||No significant difference in the ovulation rates||4||Spain||Reproductive Biomedicine Online|
|Recombinant FSH in a low-dose, step-up protocol (starting dose 75 lU/day) for up to three cycles (n = 38)|
|Leader (2006)||RCT (n = 158)||Anovulatory or oligo-ovulatory infertile women||In the absence of follicles ≥12 mm after 7 days, the daily dosage was increased by 25 IU vs. 50 IU/week||Ovulation rate||81.3% (25 IU) vs. 60.3% (50 IU)||Absolute difference: 18.6%, 95% CI (4.6 to 32.7); P < 0.009||Multicentre study (n = 18); absolute difference adjusted for centre. One treatment cycle (maximum 35 days).||Weekly increments of 25 IU in the daily dose were more effective and efficient than 50 IU increments||1b||Canada||Fertility and Sterility|
|Monofollicular development||41.3% (25 IU) vs. 21.8% (50 IU)||Absolute difference: 19.3%, 95% CI (4.7 to 34.0); P < 0.010|
|Christin-Maitre and Hugues, 2003||RCT (n = 83)||Women with anovulatory infertility due to PCOS (WHO type II), CC resistance or CC failure||Low dose step-up protocol (44 patients, 85 cycles), starting dose: 50 IU recombinant FSH/day up to 14 days of the first cycle||Monofollicular development (one follicle >16 mm at the time of HCG administration)||68.2 vs. 32% Ovulation was observed in 70.3% of the cycles using the step-up procedure as compared with 51.3% using the step-down procedure (P < 0.01)||P < 0.0001||Multi-centre study (n = 11); up to three consecutive treatment cycles||The step-up protocol using recombinant FSH (Puregon), is more efficient in obtaining a monofollicular development and ovulation than the step-down protocol, in women with CC-resistant polycystic ovaries||1b||France||Human Reproduction|
|Step-down protocol (39 patients, 72 cycles); starting dose: 100 IU recombinant FSH daily until follicular development (>9 mm) or until day 6 of stimulation in the absence of follicular development. Hereafter the dose was decreased or increased.|
|Homburg et al. (2012)||RCT (n = 302)||Infertile women with PCOS, age <40 years, first treatment cycle||CC (50–150 mg/day for 5 days)||Pregnancy rate (per cycle and cumulative) LBR||All results were in favour of recombinant FSH: pregnancy rate per first cycle 30% vs. 14.6%; pregnancy rate per woman (58% vs. 44% of women); LBR per woman (52 vs. 39%); cumulative pregnancy rate (52.1 vs. 41.2%); cumulative LBR (47.4 vs. 36.9%) within three cycles of ovulation induction||Pregnancy rate first cycle: P < 0.003; 95% CI 5.3 to 25.8; pregnancy rate per woman: P < 0.03; 95% CI 1.5 to 25.8; LBR per woman: P < 0.04; 95% CI 0.4 to 24.6; cumulative pregnancy rate: P < 0.021; 95% CI 0.4 to 24.6; cumulative LBR: P < 0.031||Up to three cycles per patient If no response: CC dose was increased in subsequent cycles. FSH was increased weekly with increments of 25 IU. Results listed are according to intention-to-treat analysis. Per protocol analysis revealed results that were more in favour of recombinant FSH||Pregnancies and live births are achieved more effectively and faster after OI with low-dose FSH than with CC. This result has to be balanced by convenience and cost in favour of CC. FSH may be an appropriate first-line treatment for some women with PCOS and anovulatory infertility.||1b||The Netherlands||Human Reproduction|
|Recombinant FSH (starting dose 50 IU/day in a step up protocol|
|Bayram et al. (2004)||RCT (n = 168)||CC resistant women with PCOS, age ≤40 years.||Laparoscopic electrocautery of the ovaries followed by CC and recombinant FSH if anovulation persisted||Ongoing viable pregnancy (at least 12 weeks pregnancy) within 12 months||56/83 (67%)||Rate ratio 1.01; 95% CI (0.81 to 1.24) P < 0.05||Non-inferiority trial||The ongoing pregnancy rate from ovulation induction with laparoscopic electrocautery followed by clomiphene citrate and recombinant follicle stimulating hormone if anovulation persisted, or recombinant follicle stimulating hormone, seems equivalent to ovulation induction with recombinant follicle stimulating hormone, but the former procedure carries a lower risk of multiple pregnancy||1b||The Netherlands||BMJ|
|Recombinant FSH||57/85 (67%)|
|Ramezanzadeh et al. (2011)||RCT (n = 67)||Infertile patients with PCOS, age <35 years||Letrozole 5 mg||Total mean number of growing follicles ≥14 mm on days 12–14||1.97 ± 1.10 vs. 1.84 ± 1.01||P = NS||First cycle patients. No intention-to-treat analysis (67 patients were randomized)||The results of this study did not show any advantage to the use of 7.5 mg/day over 5 mg/day dose of letrozole as the first line treatment for induction of ovulation in women with PCOS||1b||Iran||Archives of Gynecology and Obstetrics|
|7.5 mg day 3 − 7 of a menstrual cycle|
CC, clomiphene citrate; LFB: live birth rate; LOD, laparoscopic ovarian drilling; NS, not statistically significant; PCOS, polycystic ovary syndrome.
Clomiphene citrate can be used as first-line treatment for women with PCOS. Clomiphene citrate is inexpensive and simple to use, and may lead to ovulation in about 75% of patients. Clomiphene citrate treatment includes only a low risk of multiple gestations.
Clomiphene citrate has been used for ovulation induction for more than 5 decades (Greenblatt et al., 1961). It is administered daily for 5 days after a spontaneous or a progestogen-induced menstrual bleeding. The treatment can be initiated on cycle day 2, 3, 4 or 5 (Wu and Winkel, 1989). About 15–40% of women with PCOS are clomiphene citrate resistant (CCR) with no follicle development after a dose of 150 mg clomiphene citrate per day for 5 days (Abu Hashim et al., 2015). The definition of clomiphene citrate failure varies but is frequently defined as no conception despite ovulation during six cycles (Homburg, 2005 and ESHRE, 2008). The clomiphene citrate treatment recommendations are presented in Figure 1. The evaluation of clomiphene citrate for ovulation induction in relation to efficacy, advantages and disadvantages is presented in Figure 2.
Clomiphene citrate dosing
A meta-analysis reported the following ovulation rates after 5 days of treatment for the following different doses: 46% (50 mg), 70% (100 mg), 76% (150 mg) and 85–90% > 150 mg (Rostami-Hodjegan et al., 2004). Another study showed an ovulation rate of 73% and a pregnancy rate of 36% in a collection of data from 5268 patients (Homburg, 2005). The ovulation rates and the probability of pregnancy are reported to be similar with treatment start on day 2, 3, 4 or 5 of the cycle (Wu and Winkel, 1989). The side-effects are dose-dependent. Doses lower than 50 mg/day may be considered for women who have experienced ovarian hyper response after a dose of 50 mg/day for 5 days (Dodge et al., 1986). The ovarian response is correlated to the body weight (Dickey et al, 2002 and Lobo et al, 1982). High BMI, hyperandrogenaemia, amenorrhoea and a large ovarian volume predict a poor response to clomiphene citrate (Imani et al, 1998 and Imani et al, 2000).
A Turkish pilot study included 60 patients with PCOS who did not respond to clomiphene citrate 50 mg/day for 5 days. On cycle day 14, the patients were allocated to either clomiphene citrate 100 mg/day for 5 days (“stair-step protocol”) or progestin-induced bleeding and a new clomiphene citrate cycle where the dose was increased to 100 mg/day for 5 days (Deveci et al., 2015). The ovulation and pregnancy rates per cycle did not differ significantly between the two groups (43.3 versus 33.3% and 16.7 versus 10.0%, but the duration of treatment was shorter in the stair-step group (20.5 ± 2.0 versus 48.6 ± 2.4 days; P = 0.0001).
The recommendation is currently six clomiphene citrate cycles, as the cumulative pregnancy rate among anovulatory women with PCOS is about 46% after four cycles and 65% after six clomiphene citrate cycles (Dickey et al., 2002).
Combination of clomiphene citrate and gonadotrophins
Veltman-Verhulst et al. (2012) reported a cumulative singleton live birth rate in patients with PCOS after treatment with conventional ovulation induction with clomiphene citrate followed by gonadotrophin stimulation in cases with CCR or clomiphene citrate failure within 2 years of 78% (Veltman-Verhulst et al., 2012). This corresponds well to the birth rate of 71% reported by Eijkemans et al. (2003) on the basis of the high pregnancy rate, a multiple pregnancy rate less than 3% and absence of ovarian hyperstimulation syndrome (OHSS), the authors concluded this treatment algorithm to be a relevant option for ovulation induction in patients with PCOS (Veltman-Verhulst et al., 2012).
The low-dose, step-up protocol is recommended in the first gonadotrophin stimulation cycle in which the patient's FSH threshold value is unknown. The first step should last for a minimum of 7 days and subsequent dose increments should be small (25–37.5 IU).
Gonadotrophin stimulation is usually administered to women who are CCR as an effective second-line treatment, but can be used as first line (Abu Hashim et al, 2015 and Lopez et al, 2004). As the polycystic ovary may be sensitive to gonadotrophin stimulation, careful dosage adjustment is recommended. Factors influencing the response are as follows: dose, stimulation regimen, number of stimulation days before dose adjustments and patient characteristics (Figure 1). Gonadotrophin stimulation is associated with a risk of OHSS and multiple gestations, which can be minimized by a low-dose step-up protocol (Calaf Alsina et al, 2003 and Homburg, Howles, 1999).
The step-up protocol is characterized by a low starting dose of recombinant FSH or highly purified menotropin (37.5–50–75 IU/day), which can be increased if no response is detected after a minimum of 7 days (no increase in plasma oestradiol level/ no follicle ≥10 mm). The threshold dose, or a dose slightly below, can be used as the starting dose in subsequent cycles (Homburg and Howles, 1999). Patients with a higher body mass index (BMI) and amenorrhoea as opposed to oligomenorrhoea may have a higher threshold value (Imani et al., 2002).
In a cohort study including 945 treatment cycles in 343 women with a starting dose of 50 IU recombinant FSH/day, mono-ovulation was achieved in 61.3% of cycles (Calaf Alsina et al., 2003). Treatment was cancelled in 13.5% of cycles owing to either hyper response or spontaneous ovulation, and mild OHSS occurred in 6.8% of cases. The cumulative pregnancy rate after six treatment cycles was 53.1%, and 6.0% of the 136 clinical pregnancies were twins (Calaf Alsina et al., 2003). Another cohort study with a focus on BMI included 67 patients with PCOS in a low-dose step-up protocol with a starting dose of 50 IU recombinant FSH/day (Yildizhan et al., 2008). The median threshold recombinant FSH dose was 50 IU/day in non-obese (BMI <25 kg/m2) patients compared with 75 IU/day in obese (BMI ≥25 kg/m2) patients (P < 0.01).
In an RCT including 158 patents with POCOS and a BMI between 18–33 kg/m2, the initial dose was 50 IU recombinant FSH per day for 7 days. The dose was then increased by either 25 or 50 IU every week (randomized) if no follicles 12 mm or wider were detected. In the 25 IU-increase group, mono-ovulation (one follicle ≥16 m, and no follicles ≥12 mm) was observed in 41.3% of patients compared with 21.8% in the 50 IU-increase group (P < 0.010) (Leader, 2006). Because of the risk of hyperstimulation, 21 patients had their cycles cancelled (n = 16 in 50 IU). Seven patients had their cycles converted to IVF (n = 5 in 50 IU). Other studies have shown that the administered dose of gonadotrophins is more important for the treatment outcome than the FSH or FSH and LH preparation used (Nahuis et al, 2010 and Weiss et al, 2015).
Step-up versus step-down
In an RCT including 83 CCR patients, the step-up and step-down approaches were compared (Christin-Maitre and Hugues, 2003). The step-up approach was significantly more successful than the step-down approach in achieving mono-follicular development (68.2% versus 32.0%; P < 0.0001). Hyper stimulation (at least three follicles greater than 16 mm) was observed in 4.7% of the patients in the step-up protocol versus 36% in the step-down protocol. The two groups used the same amount of recombinant FSH, but the duration of stimulation was longer in the step-up group (Christin-Maitre and Hugues, 2003).
Clomiphene citrate versus gonadotrophins
An RCT reported the cumulative pregnancy rate and live birth rates (LBR) in first-cycle patients with PCOS (Homburg et al., 2012). Pregnancy rate and LBR were higher in low-dose recombinant FSH cycles compared with clomiphene citrate cycles. The cumulative pregnancy rate after three cycles was 41.2% for the clomiphene citrate group compared with 52.1% for the FSH group (P < 0.021). The cumulative LBR after three cycles was 36.9% for the clomiphene citrate group compared with 47.4% for the FSH group (P = 0.031).
The effect of metformin on menstrual cycle regulation is seen within 1–3 months. Metformin may be beneficial as a supplement to lifestyle intervention in relation to weight loss. Metformin improves the ovulation rate compared with placebo. Evidence that metformin improves the live birth rate in women with PCOS is lacking.
Metformin is an insulin sensitizer used in the treatment of type 2 diabetes. Because of the metabolic features related to PCOS, such as hyperinsulinaemia and insulin resistance, several clinical trials have tested the use of metformin for cycle regulation and ovulation induction in women with PCOS.
Metformin may regulate the menstrual cycle within 1–3 months of treatment in anovulatory women with PCOS (Costello, Eden, 2003, Curi et al, 2012, Mathur et al, 2008, and Sinawat et al, 2012). The daily dose is 1000–2000 mg administered in two to three daily doses in combination with a meal to minimize possible gastrointestinal side-effects.
The effect of metformin on ovulation, pregnancy and LBR may depend on the women's BMI and insulin resistance. An overview of the best efficacy of metformin alone or in combination with clomiphene citrate on the above mentioned parameters is presented in Table 3 (Johnson et al, 2010, Legro et al, 2007, Misso et al, 2013, Palomba et al, 2005, Siebert et al, 2012, Tang et al, 2012, and Xiao et al, 2012). Overall, clomiphene citrate is superior compared with metformin in achieving LBR.
|Ovulation rate||Pregnancy rate||Live birth rate|
|Metformin vs. Placebo||Metformina||Metformina||No sign. diff.a|
|Metformin vs. CC||CCc and d/No sign. diff. (BMI≤30 kg/m2)f||No sign. diff.c and b/CCe||CCd and e|
|Metformin + CC vs. Metformin||Metformin + CCe||Metformin + CCe/No sign. diff.g||Metformin + CCe/No sign. diffg|
|Metformin + CC vs. CC||Metformin + CCa and d /No sign. diff.c||Metformin + CCa and c/No sign. diff. (BMI>25 kg/m2)d||No sign. diff.a and d|
CC, clomiphene citrate.
A recent meta-analysis found a lower ovulation rate for metformin compared with clomiphene citrate (OR 0.48; P < 0.01) but no significant difference in ovulation rate was found for combined clomiphene citrate plus metformin compared with metformin (OR 1.52; 95% CI 0.95–2.45) (Xiao et al., 2012). Siebert et al. (2012) found a higher ovulation rate for the combination clomiphene citrate plus metformin compared with clompiphene citrate (OR 1.6, 95% CI 1.2 to 2.1; P < 0.00001).
The pregnancy rate is higher for metformin compared with placebo (pooled OR 2.31, 95% CI 1.52 to 3.51) (Tang et al., 2012). Xiao et al. (2012) found similar pregnancy rates for metformin compared with clomiphene citrate (OR 0.94; 95% CI 0.26–3.43) (Xiao et al., 2012). The pregnancy rate is increased when metformin is combined with clomiphene citrate versus metformin (OR 1.56; 95% CI 1.16–2.08; P < 0.003). Similar pregnancy rates data for metformin plus clomiphene citrate versus clomiphene citrate have been reported (OR 1.3; 95% CI 1.0 to 1.6; P < 0.05) (Siebert et al., 2012) (pooled OR 1.51, 95% CI 1.17 to 1.96) (Tang et al., 2012). No significant difference was found in the risk of spontaneous abortion neither for metformin versus clomiphene citrate (OR = 0.63; 0.06 to 6.47) nor for metformin plus clomiphene citrate versus metformin (OR 1.40; 95% CI 0.79 to 2.48) (Xiao et al., 2012).
Despite increased pregnancy rates for the combination of metformin plus clomiphene citrate, there is no significant effect on LBR (OR 1.16, 95% CI 0.85 to 1.56) (Tang et al., 2012). Additionally, Siebert et al. (2012) found a lower LBR for metformin compared with clomiphene (OR 0.48; 95% CI 0.31 to 0.73; P < 0.001) (Siebert et al., 2012). The same negative results applies for the combination of metformin plus clomiphene citrate versus clomiphene citrate (OR 1.16; 95% CI 0.85 to 1.56) (Tang et al., 2012).
Subgroup analyses of BMI groups found a pooled odds ratios for LBR of 0.3 (95% CI 0.17 to 0.52) and 0.34 for pregnancy rate (95% CI 0.21 to 0.55) in favour of clomiphene citrate over metformin (Tang et al., 2012) in obese women (BMI ≥30 kg/m2).
A recent meta-analysis found that metformin in combination with lifestyle intervention was associated with weight loss and improved menstrual cycle regularity compared with lifestyle intervention and placebo (any BMI) (Naderpoor et al., 2015).
Women with a BMI 27 kg/m2 or over may benefit from metformin pretreatment (pregnancy rate 49.0 versus 31.4%; P < 0.04; and LBR 35.7 versus 21.9%; P < 0.07) (Morin-Papunen et al., 2012).
Metformin in combination with gonadotrophins
A systematic review of low-quality RCTs found that metformin increased the pregnancy rate (OR 2.25; 95% CI 1.50 to 3.38) and LBR (OR 1.94; 95% CI 1.10 to 3.44) in women treated with gonadotrophins for ovulation induction (Palomba et al., 2014).
Evidence that metformin has a teratogenic effect or prevents gestational diabetes when used in the first trimester of pregnancy is lacking (Cassina et al, 2014, Sivalingam et al, 2014, and Zhuo et al, 2014). Currently, there is no indication for continuing metformin treatment during pregnancy in women with PCOS (Palomba et al, 2009 and Vanky et al, 2010).
Pregnancy rates are higher for metformin compared with placebo, but there is no evidence that metformin improves the LBR either when used alone, in combination with clomiphene citrate or when compared with clomiphene citrate (Misso et al, 2013 and Tang et al, 2012). Recent meta-analyses suggest that metformin may have a positive effect on weight regulation and could therefore be considered in overweight or obese women with PCOS (Naderpoor et al., 2015).
Overweight women with PCOS should be informed of the beneficial effect of weight loss and exercise, which increases the probability of ovulation.
Lifestyle changes can improve menstrual irregularities and insulin resistance (Curi et al, 2012 and Lass et al, 2011). Obesity is associated with increased risk of anovulation, increased androgen production and reduced ovarian responsiveness to FSH (Perales-Puchalt and Legro, 2013).
A recent meta-analysis reported a beneficial effect of lifestyle intervention on body composition (BMI, body weight and waist-to-hip ratio), hyperandrogenism (clinical, biochemical, or both), and insulin resistance in women with PCOS (Moran et al., 2011). This conclusion was supported by two additional meta-analyses (Domecq et al, 2013 and Haqq et al, 2015). Long-term follow-up studies with clinical end points such as LBR, however, are lacking.
A prospective cohort study of 69 anovulatory, infertile obese women (BMI ≥30) used diet and exercise as intervention. Within the study period of 6 months, 90% of the patients who completed the treatment achieved spontaneous ovulation. Ovulation generally occurred during the fifth month of treatment when the average weight loss was 6.5 kg, although the women still had a BMI >30 kg/m2. None of the women who failed to complete the treatment achieved spontaneous ovulation within the 6-month period (Clark et al., 1998).
An RCT of 96 overweight women who were CCR studied the efficacy of structured training (Palomba et al., 2010). A 6-week intervention of structured exercise training and hypocaloric diet significantly increased the probability of ovulation under clomiphene citrate after only one treatment cycle. The ovulation rate was four out of 32 (12.5%) in the exercise and diet group compared with three out of 32 (9.4%) in the clomiphene citrate group versus 12 out of 32 (37.5%) in the exercise and diet plus clomiphene citrate group (P < 0.035).
A cohort study of 270 women with PCOS evaluated the ovulation rate in relation to BMI. After six clomiphene citrate or gonadotrophin treatment cycles, the ovulation rate was 79% among women with a BMI of 18–24 kg/m2, 15.3% with a BMI of 30–34 kg/m2 (P < 0.001) and 12% with a BMI ≥35 kg/m2 (P < 0.001) (Al-Azemi et al., 2004).
Nybacka et al. (2011) conducted an RCT and found that dietary management and exercise, alone or in combination, are equally effective in improving reproductive function in overweight and obese women with PCOS.
A bodyweight loss of 5–10% can induce spontaneous ovulation or increase the response to clomiphene citrate (Legro et al., 2015). Even a limited weight loss can be a significant factor due to the loss of visceral fat (Ravn et al, 2013 and Yildirim et al, 2003).
Laparoscopic ovarian drilling
Minimal invasive surgery with laparoscopic ovarian drilling (LOD) could be considered as an alternative treatment in infertile PCOS women characterized by CCR, excessive or uncontrollable reaction to gonadotrophins or previous OHSS.
The mechanism of LOD is uncertain, but may be linked to the destruction of the androgen-producing cells in both the follicles and the interstitial tissue of the ovaries (Li and Ng, 2012). The lower concentrations of androgens and inhibins may increase the FSH secretion and induce follicular growth through negative feedback mechanisms (Abu Hashim, 2015). Another explanation could be the injury-mediated increased blood flow of the ovaries, which may release a cascade of local growth factors, such as insulin-like growth factor 1, interacting with FSH and thus leading to follicular growth (Abu Hashim, 2015).
A meta-analysis of subfertile women with CCR PCOS (25 RCTs) found no significant difference in the clinical pregnancy rate, birth or spontaneous abortion rates for women treated with LOD compared with clomiphene citrate plus tamoxifen, gonadotrophin or letrozole (Farquhar et al., 2012). On the contrary, they found a significantly lower LBR after LOD compared with treatment with clomiphene citrate plus metformin (OR 0.44, 95% CI 0.24 to 0.82). The number of multiple pregnancies was lower after LOD compared with gonadotrophins (OR 0.13, 95% CI 0.03 to 0.52).
Nahuis et al. (2011) found no significant difference in the long-term outcome (8–12 years) of 168 women with CCR PCOS. The cumulative singleton LBR was 86% in the group treated with LOD compared with 81% in the gonadotrophin group.
Knowledge of the long term consequences of LOD on ovarian reserve, adhesion formation and secondary infertility are limited. Available research does not support an increased risk of reduced ovarian reserve or premature ovarian failure (Api, 2009). Fernandez et al. (2011), in their review, found the complications of LOD to be rare but may include a risk of general complications of laparoscopy, general anaesthesia, damage to the adjacent organs and ligaments, bleeding, haematoma and risk of adhesion formation to the adnexa.
Letrozole is still an off-label drug in many countries, but may be an efficient treatment for ovulation induction in women with PCOS.
Letrozole is an aromatase inhibitor and has been introduced as an alternative treatment for ovulation induction in PCOS. It has recently been approved by the US Food and Drug Administration but is still an off-label drug in most European countries (Palomba, 2015). Letrozole inhibits the aromatase activity and the cytochrome P450 enzyme complex and induces an acute hypo oestrogenic state that stimulates the release of FSH (Palomba, 2015).
The largest meta-analysis to date included 26 RCTs (5560 women) and compared letrozole with placebo, clomiphene citrate with or without adjuncts, and LOD. The authors concluded that letrozole was superior to clomiphene citrate (with or without adjuncts) in relation to LBR (OR 1.34, 95% CI 1.32 to 2.04) in women with CCR or as first-line treatment, both with timed intercourse (Franik et al., 2015). Similarly, letrozole had a higher clinical pregnancy rate compared with clomiphene citrate (with or without adjuncts) in both timed intercourse (OR 1.40 95% CI: 1.18 to 1.65) and IUI (OR 1.71, 95% CI 1.30 to 2.25) (Franik et al., 2015). Additionally, fewer multiple pregnancies occurred with letrozole compared with clomiphene citrate (OR 0.38, 95% CI 0.17 to 0.84) (Franik et al., 2015). As the quality of some of the included studies was low, the conclusions should be interpreted with caution.
To date, the clinical experience of the use of letrozole for ovulation induction in Europe is limited (Palomba, 2015). The efficacy of letrozole is dependent on the patient's BMI and weight with a higher efficiency in relation to ovulation induction observed in obese women (McKnight et al., 2011).
An RCT included women with PCOS undergoing first-cycle ovulation induction and timed intercourse. The women were allocated to either 5 (n = 30) or 7.5 mg (n = 37) letrozole daily for 5 days (from day 3 of the menstrual cycle). Ovulation occurred in 90% and 89% of the patients in the two groups and the pregnancy rate per first ovulatory cycle was 25.8% (5 mg) versus 21.2% (7.5 mg). There was no advantage of using 7.5 versus 5 mg letrozole per day (Ramezanzadeh et al., 2011).
Letrozole has been shown to be teratogenic, embryo-toxic and fetotoxic in animal models (Palomba, 2015). On the other hand, previous studies in humans have demonstrated (absolute) safety for the treatment of letrozole in relation to the health of the offspring (Palomba, 2015). A 3-year follow-up from the Assessment of Multiple Intrauterine Gestations of Ovarian Stimulation (AMIGOS) and the PPPCOS-II is currently being conducted (Palomba, 2015).
Different treatment options may all lead to ovulation in women with PCOS. In the present review, the most commonly used treatments strategies for ovulation induction are discussed.
Clomiphene citrate is an efficient, inexpensive and well-tolerated drug with a well-known safety profile when dosed correctly (Palomba, 2015). This review supports the use of clomiphene citrate as first-line treatment for ovulation induction in PCOS. Theoretically, continuation of treatment for another six cycles of clomiphene citrate before switching to, for example, gonadotrophins may be cost-effective (Moolenaar et al., 2014). This issue is currently being investigated in an ongoing Dutch RCT (Nahuis et al., 2013).
Planning ovulation induction in women with PCOS requires a clinical evaluation of the patients' BMI and, if possible, their PCOS phenotype. Four major PCOS phenotypes have now been identified: hyperandrogenism and chronic anovulation (classic PCOS); hyperandrogenism and polycystic ovaries but ovulatory cycles (ovulatory PCOS); chronic anovulation and polycystic ovaries without hyperandrogenism (mild PCOS); and hyperandrogenism, chronic anovulation and polycystic ovaries (severe PCOS) (Conway et al., 2014). The natural history of PCOS and the reproductive outcome vary between the different phenotypes (Moran et al., 2015). The phenotypes including hyperandrogenism and anovulation are associated with a more severe endocrine disturbance than the phenotype, including only polycystic ovaries and anovulation (Diamanti-Kandarakis and Panidis, 2007).
Several studies have underlined the association between obesity and PCOS (Lim et al, 2012 and Moran et al, 2015). A recent review states that even though the degree of obesity varies across phenotypes, insulin resistance and reproductive and metabolic challenges are exacerbated by obesity (Moran et al., 2015). Furthermore, obesity is associated with an increased risk of adverse events for the mother and offspring during pregnancy, such as gestational diabetes, hypertension, cesarean section, macrosomia, and stillbirth (Muktabhant et al., 2015). Hence, prevention and treatment of obesity is important in the management of PCOS. Overweight and obese women should be advised to lose weight before initiating fertility treatment, as lifestyle intervention can induce spontaneous ovulation and increase the chance of pregnancy (Curi et al., 2012). It is, however, less clear if, or to what extent, clinics offer advice, support and follow-up, or whether an upper BMI, waist-to-hip ratio limit, or both, should be achieved before fertility treatment. Another important challenge is to maintain the patient's motivation during lifestyle intervention (Nybacka et al., 2011).
A meta-analysis by Naderpoor et al. (2015) suggests that metformin may improve success in weight management. Otherwise, the role of metformin in ovulation induction is controversial. Metformin regulates the menstrual cycle and improves the ovulation rate compared with placebo (Tang et al., 2012). So far, evidence that metformin improves the LBR in women with PCOS is lacking. Interestingly, metformin may have a role as pretreatment before standard assisted reproduction techniques. A recent Finnish RCT demonstrated improved pregnancy rates after 3–9 months of metformin before assisted reproduction techniques (Morin-Papunen et al., 2012). Unfortunately, the women only used metformin for a shorter period in most studies describing the efficacy of metformin in relation to ovulation induction. Therefore, an eventual effect of a longer metformin pretreatment remains to be shown.
In a selected group of women with a history of OHSS or uncontrollable stimulations, LOD should be treated as an alternative treatment, as this treatment modality is inferior to clomiphene citrate and gonadotrophins (as first-line treatments) (Abuelghar et al, 2014, Bayram et al, 2004, Farquhar et al, 2012, and Moazami Goudarzi et al, 2014). Furthermore, data on the long-term consequences are insufficient (Fernandez et al., 2011).
Letrozole is still not registered for ovulation induction in Europe, and data on long term follow-up have not yet been published. An American study by Legro et al. (2014) included patients with a very high BMI, which is rarely seen in European studies, without any lifestyle interventions (Legro et al., 2014). This illustrates the influence of different country settings and populations on treatment strategies. In countries in which letrozole is registered for ovulation induction, it may be considered in (overweight) women who are CCR with PCOS. In countries in which letrozole is still an off-label drug, however, we advocate the use of gonadotrophins. Although gonadotrophin treatment is more expensive and requires extensive monitoring (Farquhar et al., 2004), a careful step-up protocol with serial ultrasound scans provides a high chance of pregnancy and a low risk of multiple gestations (Christin-Maitre, Hugues, 2003 and Homburg et al, 2012). Furthermore, strict cancellation criteria should be applied to minimize the risk of multiple gestations.
Access to treatment, willingness (Poder et al., 2014) or possibility to pay for ovulation induction, reimbursement policies, legal aspects and expectations for the duration of treatment may influence the choice of treatment strategy for ovulation induction. Furthermore, clinicians should consider the cost of a treatment. A recent retrospective study from Belgium, including 78 women with CCR PCOS showed that the societal cost before an ongoing pregnancy was less after menotropin treatment compared with LOD surgery (De Frene et al., 2015). In a Dutch RCT, van Wely et al. (2004) concluded that the costs until an ongoing pregnancy occurred were comparable with a strategy starting with LOD versus recombinant FSH. Contrarily, Farquhar et al. (2004) found that LOD was cost-effective compared with gonadotrophin stimulation (van Wely et al., 2004). In line with this, in a long-term follow-up study Nahuis et al. (2012) found a lower cost per live birth after LOD-only compared with gonadotrophins. In a Belgian study, the societal cost was mostly ascribed to productivity loss after LOD owing to a long recovery phase, which may explain the conflicting conclusions between some of the studies (De Frene et al., 2015).
Regarding treatment after six cycles with clompihene citrate failure, an ongoing Dutch trial is evaluating the cost-effectiveness of further six treatment cycles with either clomiphene citrate or gonadotrophin stimulation with or without intrauterine insemination (Nahuis et al., 2013).
Future treatment strategies for ovulation induction may include adjuncts such as the insulin-sensitizing agent myo-inositol. Recent studies found that myo-inositol improved the ovulation and pregnancy rate in insulin-resistant patients with PCOS when given alone or in combination with clomiphene citrate (Kamenov et al., 2015) or as a supplementation in a low-dose step-down protocol (Morgante et al., 2011). It may also improve oocyte and embryo quality in IVF of patients with PCOS (Pacchiarotti et al., 2016) and an animal study in rats demonstrated that myo-inositol was effective in preventing OHSS (Turan et al., 2015). The conclusion from a recent Consensus Conference indicated that Inositol nutritional supplementation (myo-inositol) improved the treatment outcomes in patients with PCOS (Bevilacqua et al., 2015). More large-scale studies are needed to finally establish the role of myo-inositol in ovulation induction treatment.
In conclusion, the understanding of the cause, definition and treatment of PCOS has evolved over time. Although clomiphene citrate as treatment modality has existed for more than 50 years, an increased awareness of the effect of obesity and different PCOS phenotypes has emerged. Accordingly, ovulation induction in women with PCOS has to be individualized according to weight, treatment efficacy and patient compliance, with the aim of achieving mono-ovulation and subsequently the birth of a singleton baby.
- Abu Hashim et al, 2015 H. Abu Hashim, O. Foda, E. Ghayaty. Combined metformin-clomiphene in clomiphene-resistant polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Acta Obstet. Gynecol. Scand. 2015;94:921-930 Crossref
- Abu Hashim, 2015 H. Abu Hashim. Predictors of success of laparoscopic ovarian drilling in women with polycystic ovary syndrome: an evidence-based approach. Arch. Gynecol. Obstet. 2015;291:11-18 Crossref
- Abuelghar et al, 2014 W.M. Abuelghar, H.A. Bayoumy, M.I. Ellaithy, M.S. Khalil. Women with clomiphene citrate resistant polycystic ovarian disease: predictors of spontaneous ovulation after laparoscopic ovarian drilling. Eur. J. Obstet. Gynecol. Reprod. Biol. 2014;175:178-185 Crossref
- Al-Azemi et al, 2004 M. Al-Azemi, F.E. Omu, A.E. Omu. The effect of obesity on the outcome of infertility management in women with polycystic ovary syndrome. Arch. Gynecol. Obstet. 2004;270:205-210 Crossref
- Alebic et al, 2015 M.S. Alebic, N. Stojanovic, A. Duhamel, D. Dewailly. The phenotypic diversity in per-follicle anti-Mullerian hormone production in polycystic ovary syndrome. Hum. Reprod. 2015;30:1927-1933 Crossref
- Api, 2009 M. Api. Is ovarian reserve diminished after laparoscopic ovarian drilling?. Gynecol. Endocrinol. 2009;25:159-165 Crossref
- Bayram et al, 2004 N. Bayram, M. van Wely, E.M. Kaaijk, P.M. Bossuyt, F. van der Veen. Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial. BMJ. 2004;328:192 Crossref
- Bevilacqua et al, 2015 A. Bevilacqua, G. Carlomagno, S. Gerli, M. Montanino Oliva, P. Devroey, A. Lanzone, C. Soulange, F. Facchinetti, G. Carlo Di Renzo, M. Bizzarri, M. Hod, P. Cavalli, R. D'Anna, S. Benvenga, T.T. Chiu, Z.A. Kamenov. Results from the international consensus conference on myo-inositol and D-chiro-inositol in obstetrics and gynecology–assisted reproduction technology. Gynecol. Endocrinol. 2015;31:441-446
- Calaf Alsina et al, 2003 J. Calaf Alsina, J.A. Ruiz Balda, A. Romeu Sarrio, V. Caballero Fernandez, I. Cano Trigo, J.L. Gomez Parga, C. Gonzalez Batres, F.J. Rodriguez Escudero. Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial. BJOG. 2003;110:1072-1077
- Cassina et al, 2014 M. Cassina, M. Dona, E. Di Gianantonio, P. Litta, M. Clementi. First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis. Hum. Reprod. Update. 2014;20:656-669 Crossref
- Christin-Maitre, Hugues, 2003 S. Christin-Maitre, J.N. Hugues. A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum. Reprod. 2003;18:1626-1631 Crossref
- Clark et al, 1998 A.M. Clark, B. Thornley, L. Tomlinson, C. Galletley, R.J. Norman. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum. Reprod. 1998;13:1502-1505 Crossref
- Conway et al, 2014 G. Conway, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, S. Franks, A. Gambineri, F. Kelestimur, D. Macut, D. Micic, R. Pasquali, M. Pfeifer, D. Pignatelli, M. Pugeat, B.O. Yildiz. The polycystic ovary syndrome: a position statement from the European society of endocrinology. Eur. J. Endocrinol. 2014;171:P1-P29 Crossref
- Costello, Eden, 2003 M.F. Costello, J.A. Eden. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil. Steril. 2003;79:1-13 Crossref
- Curi et al, 2012 D.D. Curi, A.M. Fonseca, J.A. Marcondes, J.A. Almeida, V.R. Bagnoli, J.M. Soares Jr., E.C. Baracat. Metformin versus lifestyle changes in treating women with polycystic ovary syndrome. Gynecol. Endocrinol. 2012;28:182-185 Crossref
- De Frene et al, 2015 V. De Frene, J. Gerris, S. Weyers, M. Dhont, S. Vansteelandt, L. Annemans, P. De Sutter. Gonadotropin therapy versus laparoscopic ovarian drilling in clomiphene citrate-resistant polycystic ovary syndrome patients: a retrospective cost-effectiveness analysis. Gynecol. Obstet. Invest. 2015;80:164-169
- Deveci et al, 2015 C.D. Deveci, B. Demir, O. Sengul, B. Dilbaz, U. Goktolga. Clomiphene citrate “stair-step” protocol vs. traditional protocol in patients with polycystic ovary syndrome: a randomized controlled trial. Arch. Gynecol. Obstet. 2015;291:179-184 Crossref
- Dewailly et al, 2011 D. Dewailly, H. Gronier, E. Poncelet, G. Robin, M. Leroy, P. Pigny, A. Duhamel, S. Catteau-Jonard. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum. Reprod. 2011;26:3123-3129 Crossref
- Diamanti-Kandarakis, Panidis, 2007 E. Diamanti-Kandarakis, D. Panidis. Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clin. Endocrinol. (Oxf). 2007;67:735-742 Crossref
- Dickey et al, 2002 R.P. Dickey, S.N. Taylor, Lu P.Y., B.M. Sartor, P.H. Rye, R. Pyrzak. Effect of diagnosis, age, sperm quality, and number of preovulatory follicles on the outcome of multiple cycles of clomiphene citrate-intrauterine insemination. Fertil. Steril. 2002;78:1088-1095 Crossref
- Dodge et al, 1986 S.T. Dodge, R.C. Strickler, D.W. Keller. Ovulation induction with low doses of clomiphene citrate. Obstet. Gynecol. 1986;67:63S-65S Crossref
- Domecq et al, 2013 J.P. Domecq, G. Prutsky, R.J. Mullan, A. Hazem, V. Sundaresh, M.B. Elamin, O.J. Phung, Wang A., K. Hoeger, R. Pasquali, P. Erwin, A. Bodde, V.M. Montori, M.H. Murad. Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2013;98:4655-4663 Crossref
- Duijkers, Klipping, 2010 I.J. Duijkers, C. Klipping. Polycystic ovaries, as defined by the 2003 Rotterdam consensus criteria, are found to be very common in young healthy women. Gynecol. Endocrinol. 2010;26:152-160 Crossref
- Eijkemans et al, 2003 M.J. Eijkemans, B. Imani, A.G. Mulders, J.D. Habbema, B.C. Fauser. High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2). Hum. Reprod. 2003;18:2357-2362 Crossref
- ESHRE, 2008 ESHRE. Consensus on infertility treatment related to polycystic ovary syndrome. Hum. Reprod. 2008;23:462-477
- ESHRE Capri Workshop Group, 2012 ESHRE Capri Workshop Group. Health and fertility in World Health Organization group 2 anovulatory women. Hum. Reprod. Update. 2012;18:586-599
- ESHRE REA-SPCWG, 2004 ESHRE REA-SPCWG. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 2004;19:41-47
- Farquhar et al, 2012 C. Farquhar, J. Brown, J. Marjoribanks. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst. Rev. 2012;(6) CD001122
- Farquhar et al, 2004 C.M. Farquhar, K. Williamson, P.M. Brown, J. Garland. An economic evaluation of laparoscopic ovarian diathermy versus gonadotrophin therapy for women with clomiphene citrate resistant polycystic ovary syndrome. Hum. Reprod. 2004;19:1110-1115 Crossref
- Fernandez et al, 2011 H. Fernandez, M. Morin-Surruca, A. Torre, E. Faivre, X. Deffieux, A. Gervaise. Ovarian drilling for surgical treatment of polycystic ovarian syndrome: a comprehensive review. Reprod. Biomed. Online. 2011;22:556-568 Crossref
- Franik et al, 2015 S. Franik, J.A. Kremer, W.L. Nelen, C. Farquhar, J. Marjoribanks. Aromatase inhibitors for subfertile women with polycystic ovary syndrome: summary of a cochrane review. Fertil. Steril. 2015;103:353-355 Crossref
- Greenblatt et al, 1961 R.B. Greenblatt, W.E. Barfield, E.C. Jungck, A.W. Ray. Induction of ovulation with MRL/41. Preliminary report. JAMA. 1961;178:101-104 Crossref
- Haqq et al, 2015 L. Haqq, J. McFarlane, G. Dieberg, N. Smart. The effect of lifestyle intervention on body composition, glycaemic control and cardio-respiratory fitness in women with polycystic ovarian syndrome: a systematic review and meta-analysis. Int. J. Sport Nutr. Exerc. Metab. 2015;25:533-540
- Homburg, 2005 R. Homburg. Clomiphene citrate–end of an era? A mini-review. Hum. Reprod. 2005;20:2043-2051 Crossref
- Homburg, Howles, 1999 R. Homburg, C.M. Howles. Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Hum. Reprod. Update. 1999;5:493-499 Crossref
- Homburg et al, 2012 R. Homburg, M.L. Hendriks, T.E. Konig, R.A. Anderson, A.H. Balen, M. Brincat, T. Child, M. Davies, T. D'Hooghe, A. Martinez, M. Rajkhowa, R. Rueda-Saenz, P. Hompes, C.B. Lambalk. Clomifene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study. Hum. Reprod. 2012;27:468-473 Crossref
- Imani et al, 1998 B. Imani, M.J. Eijkemans, E.R. te Velde, J.D. Habbema, B.C. Fauser. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J. Clin. Endocrinol. Metab. 1998;83:2361-2365
- Imani et al, 2000 B. Imani, M.J. Eijkemans, F.H. de Jong, N.N. Payne, P. Bouchard, L.C. Giudice, B.C. Fauser. Free androgen index and leptin are the most prominent endocrine predictors of ovarian response during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J. Clin. Endocrinol. Metab. 2000;85:676-682
- Imani et al, 2002 B. Imani, M.J. Eijkemans, G.H. Faessen, P. Bouchard, L.C. Giudice, B.C. Fauser. Prediction of the individual follicle-stimulating hormone threshold for gonadotropin induction of ovulation in normogonadotropic anovulatory infertility: an approach to increase safety and efficiency. Fertil. Steril. 2002;77:83-90 Crossref
- Johnson et al, 2010 N.P. Johnson, A.W. Stewart, J. Falkiner, C.M. Farquhar, S. Milsom, V.P. Singh, Q.L. Okonkwo, K.L. Buckingham. PCOSMIC: a multi-centre randomized trial in women with PolyCystic ovary syndrome evaluating metformin for infertility with clomiphene. Hum. Reprod. 2010;25:1675-1683 Crossref
- Kamenov et al, 2015 Z. Kamenov, G. Kolarov, A. Gateva, G. Carlomagno, A.D. Genazzani. Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecol. Endocrinol. 2015;31:131-135 Crossref
- Kristensen et al, 2010 S.L. Kristensen, C.H. Ramlau-Hansen, E. Ernst, S.F. Olsen, J.P. Bonde, A. Vested, G. Toft. A very large proportion of young Danish women have polycystic ovaries: is a revision of the Rotterdam criteria needed?. Hum. Reprod. 2010;25:3117-3122 Crossref
- Lass et al, 2011 N. Lass, M. Kleber, K. Winkel, R. Wunsch, T. Reinehr. Effect of lifestyle intervention on features of polycystic ovarian syndrome, metabolic syndrome, and intima-media thickness in obese adolescent girls. J. Clin. Endocrinol. Metab. 2011;96:3533-3540 Crossref
- Lauritsen et al, 2015 M.P. Lauritsen, A. Pinborg, A. Loft, J.H. Petersen, A.L. Mikkelsen, M.R. Bjerge, A. Nyboe Andersen. Revised criteria for PCOS in WHO Group II anovulatory infertility – a revival of hypothalamic amenorrhoea?. Clin. Endocrinol. (Oxf). 2015;82:584-591 Crossref
- Leader, 2006 A. Leader. Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low-dose step-up protocol with weekly increments of 25 international units of follicle-stimulating hormone. Fertil. Steril. 2006;85:1766-1773 Crossref
- Legro et al, 2007 R.S. Legro, H.X. Barnhart, W.D. Schlaff, B.R. Carr, M.P. Diamond, S.A. Carson, M.P. Steinkampf, C. Coutifaris, P.G. McGovern, N.A. Cataldo, G.G. Gosman, J.E. Nestler, L.C. Giudice, P.C. Leppert, E.R. Myers. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N. Engl. J. Med. 2007;356:551-566 Crossref
- Legro et al, 2014 R.S. Legro, R.G. Brzyski, M.P. Diamond, C. Coutifaris, W.D. Schlaff, P. Casson, G.M. Christman, Huang H., Yan Q., R. Alvero, D.J. Haisenleder, K.T. Barnhart, G.W. Bates, R. Usadi, S. Lucidi, V. Baker, J.C. Trussell, S.A. Krawetz, P. Snyder, D. Ohl, N. Santoro, E. Eisenberg, Zhang H. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N. Engl. J. Med. 2014;371:119-129 Crossref
- Legro et al, 2015 R.S. Legro, W.C. Dodson, P.M. Kris-Etherton, A.R. Kunselman, C.M. Stetter, N.I. Williams, C.L. Gnatuk, S.J. Estes, J. Fleming, K.C. Allison, D.B. Sarwer, C. Coutifaris, A. Dokras. Randomized controlled trial of preconception interventions in infertile women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2015;100:4048-4058 jc20152778
- Li, Ng, 2012 Li R.H., E.H. Ng. Management of anovulatory infertility. Best Pract. Res. Clin. Obstet. Gynaecol. 2012;26:757-768 Crossref
- Lim et al, 2012 S.S. Lim, M.J. Davies, R.J. Norman, L.J. Moran. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update. 2012;18:618-637 Crossref
- Lobo et al, 1982 R.A. Lobo, M. Gysler, C.M. March, U. Goebelsmann, D.R. Mishell Jr. Clinical and laboratory predictors of clomiphene response. Fertil. Steril. 1982;37:168-174
- Lopez et al, 2004 E. Lopez, J. Gunby, S. Daya, J.J. Parrilla, L. Abad, J. Balasch. Ovulation induction in women with polycystic ovary syndrome: randomized trial of clomiphene citrate versus low-dose recombinant FSH as first line therapy. Reprod. Biomed. Online. 2004;9:382-390 Crossref
- Mathur et al, 2008 R. Mathur, C.J. Alexander, J. Yano, B. Trivax, R. Azziz. Use of metformin in polycystic ovary syndrome. Am. J. Obstet. Gynecol. 2008;199:596-609 Crossref
- McKnight et al, 2011 K.K. McKnight, J.L. Nodler, J.J. Cooper Jr., V.R. Chapman, S.P. Cliver, G.W. Bates Jr. Body mass index-associated differences in response to ovulation induction with letrozole. Fertil. Steril. 2011;96:1206-1208 Crossref
- Misso et al, 2013 M.L. Misso, M.F. Costello, M. Garrubba, J. Wong, R. Hart, L. Rombauts, A.M. Melder, R.J. Norman, H.J. Teede. Metformin versus clomiphene citrate for infertility in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update. 2013;19:2-11 Crossref
- Moazami Goudarzi et al, 2014 Z. Moazami Goudarzi, H. Fallahzadeh, A. Aflatoonian, M. Mirzaei. Laparoscopic ovarian electrocautery versus gonadotropin therapy in infertile women with clomiphene citrate-resistant polycystic ovary syndrome: a systematic review and meta-analysis. Iran J. Reprod. Med. 2014;12:531-538
- Moolenaar et al, 2014 L.M. Moolenaar, M.J. Nahuis, P.G. Hompes, F. van der Veen, B.W. Mol. Cost-effectiveness of treatment strategies in women with PCOS who do not conceive after six cycles of clomiphene citrate. Reprod. Biomed. Online. 2014;28:606-613 Crossref
- Moran et al, 2011 L.J. Moran, S.K. Hutchison, R.J. Norman, H.J. Teede. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst. Rev. 2011;7 CD007506
- Moran et al, 2015 L.J. Moran, R.J. Norman, H.J. Teede. Metabolic risk in PCOS: phenotype and adiposity impact. Trends Endocrinol. Metab. 2015;26:136-143 Crossref
- Morgante et al, 2011 G. Morgante, R. Orvieto, A. Di Sabatino, M.C. Musacchio, V. De Leo. The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen. Fertil. Steril. 2011;95:2642-2644 Crossref
- Morin-Papunen et al, 2012 L. Morin-Papunen, A.S. Rantala, L. Unkila-Kallio, A. Tiitinen, M. Hippelainen, A. Perheentupa, H. Tinkanen, R. Bloigu, K. Puukka, A. Ruokonen, J.S. Tapanainen. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. J. Clin. Endocrinol. Metab. 2012;97:1492-1500 Crossref
- Muktabhant et al, 2015 B. Muktabhant, T.A. Lawrie, P. Lumbiganon, M. Laopaiboon. Diet or exercise, or both, for preventing excessive weight gain in pregnancy. Cochrane Database Syst. Rev. 2015;(6) CD007145
- Naderpoor et al, 2015 N. Naderpoor, S. Shorakae, B. de Courten, M.L. Misso, L.J. Moran, H.J. Teede. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum. Reprod. Update. 2015;21:560-574 Crossref
- Nahuis et al, 2010 M. Nahuis, F. van der Veen, J. Oosterhuis, B.W. Mol, P. Hompes, M. van Wely. Review of the safety, efficacy, costs and patient acceptability of recombinant follicle-stimulating hormone for injection in assisting ovulation induction in infertile women. Int. J. Womens Health. 2010;1:205-211
- Nahuis et al, 2011 M.J. Nahuis, N. Kose, N. Bayram, H.J. van Dessel, D.D. Braat, C.J. Hamilton, P.G. Hompes, P.M. Bossuyt, B.W. Mol, F. van der Veen, M. van Wely. Long-term outcomes in women with polycystic ovary syndrome initially randomized to receive laparoscopic electrocautery of the ovaries or ovulation induction with gonadotrophins. Hum. Reprod. 2011;26:1899-1904 Crossref
- Nahuis et al, 2012 M.J. Nahuis, E. Oude Lohuis, N. Kose, N. Bayram, P. Hompes, G.J. Oosterhuis, E.M. Kaaijk, B.J. Cohlen, P.P. Bossuyt, F. van der Veen, B.W. Mol, M. van Wely. Long-term follow-up of laparoscopic electrocautery of the ovaries versus ovulation induction with recombinant FSH in clomiphene citrate-resistant women with polycystic ovary syndrome: an economic evaluation. Hum. Reprod. 2012;27:3577-3582 Crossref
- Nahuis et al, 2013 M.J. Nahuis, N.S. Weiss, F. van der Veen, B.W. Mol, P.G. Hompes, J. Oosterhuis, N.B. Lambalk, J.M. Smeenk, C.A. Koks, R.J. van Golde, J.S. Laven, B.J. Cohlen, K. Fleischer, A.J. Goverde, M.H. Gerards, N.F. Klijn, L.C. Nekrui, I.A. van Rooij, D.A. Hoozemans, M. van Wely. The M-OVIN study: does switching treatment to FSH and / or IUI lead to higher pregnancy rates in a subset of women with world health organization type II anovulation not conceiving after six ovulatory cycles with clomiphene citrate – a randomised controlled trial. BMC Womens Health. 2013;13:42 Crossref
- Norman et al, 2004 R.J. Norman, M. Noakes, Wu R., M.J. Davies, L. Moran, Wang J.X. Improving reproductive performance in overweight/obese women with effective weight management. Hum. Reprod. Update. 2004;10:267-280 Crossref
- Nybacka et al, 2011 A. Nybacka, K. Carlstrom, A. Stahle, S. Nyren, P.M. Hellstrom, A.L. Hirschberg. Randomized comparison of the influence of dietary management and/or physical exercise on ovarian function and metabolic parameters in overweight women with polycystic ovary syndrome. Fertil. Steril. 2011;96:1508-1513
- Pacchiarotti et al, 2016 A. Pacchiarotti, G. Carlomagno, G. Antonini, A. Pacchiarotti. Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome. Gynecol. Endocrinol. 2016;32:69-73
- Palomba, 2015 S. Palomba. Aromatase inhibitors for ovulation induction. J. Clin. Endocrinol. Metab. 2015;100:1742-1747 Crossref
- Palomba et al, 2005 S. Palomba, F. Orio Jr., A. Falbo, F. Manguso, T. Russo, T. Cascella, A. Tolino, E. Carmina, A. Colao, F. Zullo. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2005;90:4068-4074 Crossref
- Palomba et al, 2009 S. Palomba, A. Falbo, F. Orio Jr., F. Zullo. Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Fertil. Steril. 2009;92:1646-1658 Crossref
- Palomba et al, 2010 S. Palomba, A. Falbo, F. Giallauria, T. Russo, M. Rocca, A. Tolino, F. Zullo, F. Orio. Six weeks of structured exercise training and hypocaloric diet increases the probability of ovulation after clomiphene citrate in overweight and obese patients with polycystic ovary syndrome: a randomized controlled trial. Hum. Reprod. 2010;25:2783-2791 Crossref
- Palomba et al, 2014 S. Palomba, A. Falbo, G.B. La Sala. Metformin and gonadotropins for ovulation induction in patients with polycystic ovary syndrome: a systematic review with meta-analysis of randomized controlled trials. Reprod. Biol. Endocrinol. 2014;12:3 Crossref
- Perales-Puchalt, Legro, 2013 A. Perales-Puchalt, R.S. Legro. Ovulation induction in women with polycystic ovary syndrome. Steroids. 2013;78:767-772 Crossref
- Phillips et al, 2009 B. Phillips, C. Ball, D. Sackett, D. Badenoch, S. Straus, B. Haynes, M. Dawes. Oxford Centre for Evidence-based Medicine – Levels of Evidence. http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/ (2009) Oxford Center of Evidence Based Medicineaccessed 12.11.14
- Poder et al, 2014 T.G. Poder, He J., C. Simard, J.C. Pasquier. Willingness to pay for ovulation induction treatment in case of WHO II anovulation: a study using the contingent valuation method. Patient Prefer Adherence. 2014;8:1337-1346 Crossref
- Ramezanzadeh et al, 2011 F. Ramezanzadeh, R. Nasiri, M. Sarafraz Yazdi, M. Baghrei. A randomized trial of ovulation induction with two different doses of Letrozole in women with PCOS. Arch. Gynecol. Obstet. 2011;284:1029-1034 Crossref
- Ravn et al, 2013 P. Ravn, A.G. Haugen, D. Glintborg. Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss. Minerva Endocrinol. 2013;38:59-76
- Rostami-Hodjegan et al, 2004 A. Rostami-Hodjegan, M.S. Lennard, G.T. Tucker, W.L. Ledger. Monitoring plasma concentrations to individualize treatment with clomiphene citrate. Fertil. Steril. 2004;81:1187-1193 Crossref
- Siebert et al, 2012 T.I. Siebert, M.I. Viola, D.W. Steyn, T.F. Kruger. Is metformin indicated as primary ovulation induction agent in women with PCOS? A systematic review and meta-analysis. Gynecol. Obstet. Invest. 2012;73:304-313 Crossref
- Sinawat et al, 2012 S. Sinawat, P. Buppasiri, P. Lumbiganon, P. Pattanittum. Long versus short course treatment with metformin and clomiphene citrate for ovulation induction in women with PCOS. Cochrane Database Syst. Rev. 2012;(10) CD006226
- Sivalingam et al, 2014 V.N. Sivalingam, J. Myers, S. Nicholas, A.H. Balen, E.J. Crosbie. Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications. Hum. Reprod. Update. 2014;20:853-868 Crossref
- Tang et al, 2012 Tang T., J.M. Lord, R.J. Norman, E. Yasmin, A.H. Balen. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst. Rev. 2012;(5) CD003053
- Turan et al, 2015 G.A. Turan, F. Eskicioglu, O.N. Sivrikoz, H. Cengiz, S. Adakan, E.B. Gur, S. Tatar, N. Sahin, O. Yilmaz. Myo-inositol is a promising treatment for the prevention of ovarian hyperstimulation syndrome (OHSS): an animal study. Arch. Gynecol. Obstet. 2015;292:1163-1171
- van Wely et al, 2004 M. van Wely, N. Bayram, F. van der Veen, P.M. Bossuyt. An economic comparison of a laparoscopic electrocautery strategy and ovulation induction with recombinant FSH in women with clomiphene citrate-resistant polycystic ovary syndrome. Hum. Reprod. 2004;19:1741-1745 Crossref
- Vanky et al, 2010 E. Vanky, S. Stridsklev, R. Heimstad, P. Romundstad, K. Skogoy, O. Kleggetveit, S. Hjelle, P. von Brandis, T. Eikeland, K. Flo, K.F. Berg, G. Bunford, A. Lund, C. Bjerke, I. Almas, A.H. Berg, A. Danielson, G. Lahmami, S.M. Carlsen. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J. Clin. Endocrinol. Metab. 2010;95:E448-E455 Crossref
- Veltman-Verhulst et al, 2012 S.M. Veltman-Verhulst, B.C. Fauser, M.J. Eijkemans. High singleton live birth rate confirmed after ovulation induction in women with anovulatory polycystic ovary syndrome: validation of a prediction model for clinical practice. Fertil. Steril. 2012;98:761-768 e1
- Weiss et al, 2015 N.S. Weiss, M. Nahuis, N. Bayram, B.W. Mol, F. Van der Veen, M. van Wely. Gonadotrophins for ovulation induction in women with polycystic ovarian syndrome. Cochrane Database Syst. Rev. 2015;(9) CD010290
- Wijeyaratne et al, 2011 C.N. Wijeyaratne, A. Seneviratne Rde, S. Dahanayake, V. Kumarapeli, E. Palipane, N. Kuruppu, C. Yapa, A. Seneviratne Rde, A.H. Balen. Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic. Hum. Reprod. 2011;26:202-213 Crossref
- Wu, Winkel, 1989 Wu C.H., C.A. Winkel. The effect of therapy initiation day on clomiphene citrate therapy. Fertil. Steril. 1989;52:564-568
- Xiao et al, 2012 Xiao J., Chen S., Zhang C., Chang S. The effectiveness of metformin ovulation induction treatment in patients with PCOS: a systematic review and meta-analysis. Gynecol. Endocrinol. 2012;28:956-960 Crossref
- Yildirim et al, 2003 B. Yildirim, N. Sabir, B. Kaleli. Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil. Steril. 2003;79:1358-1364 Crossref
- Yildizhan et al, 2008 R. Yildizhan, E. Adali, A. Kolusari, M. Kurdoglu, B. Yildizhan, H.G. Sahin, M. Kamaci. Ovarian stimulation in obese and non-obese polycystic ovary syndrome using a low-dose step-up regimen with two different starting doses of recombinant follicle-stimulating hormone. J. Int. Med. Res. 2008;36:1197-1204 Crossref
- Zhuo et al, 2014 Zhuo Z., Wang A., Yu H. Effect of metformin intervention during pregnancy on the gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and meta-analysis. J Diabetes Res. 2014;2014 381231
Kathrine Birch Petersen is a specialist in obstetrics and gynaecology. She is affiliated to the Fertility Clinic at Rigshospitalet. Primary research areas are female infertility, Fertility Awareness, preconception counselling and intentions in family formations. She is currently completing a PhD from the University of Copenhagen regarding the Fertility Assessment and Counselling Clinic at Rigshospitalet, the first of its kind in the world.
a Fertility Clinic, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark
b Department of Gynecology/Obstetrics, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark
c Fertility Clinic and Department of Gynecology, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark
d Department of Gynecology/Obstetrics, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, 2730 Herlev, Denmark
e Fertility Clinic and Department of Gynecology/Obstetrics, Holbæk Hospital, Copenhagen University Hospital, Smedelundsgade 60, 4300 Holbæk, Denmark
* Corresponding author.
© 2016 Reproductive Healthcare Ltd., Published by Elsevier B.V.